How can Medicaid pay for cell and gene therapies?

12/17/24 • 25 min

Cell and gene therapies have been grabbing news headlines, both for their potential to cure rare diseases and for their million-dollar price tags. Milliman pharmacists and healthcare experts explain why state Medicaid agencies are particularly affected and the strategies many are using for predicting uptake and covering these high costs.

You can read the episode transcript on our website.

You can read the episode transcript on our website.

Previous Episode

Healthcare costs in a presidential election year

Healthcare costs are a hot topic as we approach open enrollment and the presidential election. In this episode of Critical Point, host Deana Bell sits down with Dave Liner and Jason Clarkson, principals at Milliman and co-authors of the Milliman Medical Index (MMI), to discuss the key drivers of 2024’s healthcare costs. They dive into the effects of government programs like Medicaid and the Inflation Reduction Act, the rising use of weight loss medications, and how these factors are shaping healthcare costs for Americans on employer-sponsored insurance. Learn how policy changes and market trends could impact your healthcare expenses and decisions in the coming year.
You can read the episode transcript on our website.

Next Episode

Artificial intelligence and insurance, part 3: Global regulations and trends

AI has taken the world by storm—but not all insurance companies, or countries, are approaching the technology the same way. On this special episode of Critical Point, experts from Munich Re and Milliman who work across five continents come together for a global conversation exploring how insurers and regulators are approaching AI around the world. Plus, don’t miss Part 1 and Part 2 of this series on AI and insurance.

You can read the episode transcript on our website.

Critical Point - How can Medicaid pay for cell and gene therapies?

Transcript

Announcer: This podcast is intended solely for educational purposes and presents information of a general nature. It is not intended to guide or determine any specific individual situation, and persons should consult qualified professionals before taking specific action. The views expressed in this podcast are those of the speakers and not those of Milliman.

Melanie Kuester: Hello and welcome to Critical Point, brought to you by Milliman. I'm Melanie Kuester. I'm a clinical pharmacist an